1415971-16-2

Upstream product

• 55362-80-6 9-bromononan-1-ol 
• 124388-97-2 9-bromononanal 
• 59014-60-7 2-(9-bromononyl)-1,3-dioxacyclopentane 
• 1415971-15-1 (piperidin-4-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate hydrochloride 
• 1415971-14-0 tert-butyl 4-((2-cyclohexyl-2-hydroxy-2-phenylacetyloxy)methyl)piperidine-1-carboxylate 
• 158407-04-6 tert-butyl 4-(bromomethyl)piperidine-1-carboxylate 
• 4335-77-7 cyclohexylmandelic acid 

Downstream Products

• 1415971-17-3 (1-(10-oxodecyl)piperidin-4-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate 
• 1415970-74-9 (1-(9-((2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate 

Relevant academic research and scientific papers

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds of general formula (I), acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.